Results from Boehringer Ingelheim's afatinib Phase III lung cancer trial

[News]

Highly anticipated results from LUX-Lung 3, the pivotal Phase III lung cancer trial investigating Boehringer Ingelheim's front running oncology investigational compound, the ErbB Family Blocker afatinib, in patients with EGFR mutations, will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012.

More... (http://www.news-medical.net/news/20120421/Results-from-Boehringer-Ingelheims-afatinib-Phase-III-lung-cancer-trial.aspx)